Your shopping cart is currently empty

Guanfu base A is a potent noncompetitive CYP2D6 inhibitor (Ki: 1.20 μM in HLMs; Ki: 0.37 μM for rCYP2D6). It also inhibits HERG channel current.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $57 | - | In Stock | |
| 5 mg | $135 | - | In Stock | |
| 10 mg | $202 | - | In Stock | |
| 25 mg | $342 | - | In Stock | |
| 50 mg | $489 | - | In Stock | |
| 100 mg | $678 | - | In Stock | |
| 200 mg | $918 | - | In Stock |
| Description | Guanfu base A is a potent noncompetitive CYP2D6 inhibitor (Ki: 1.20 μM in HLMs; Ki: 0.37 μM for rCYP2D6). It also inhibits HERG channel current. |
| Targets&IC50 | CYP2D6:0.37 μM (Ki, cell free) |
| In vitro | Guanfu base A does not inhibit mouse or rat CYP2Ds and shows no inhibition of human recombinant 2C8, 2C19, CYP1A2, 2A6, 3A4, or 3A5, but demonstrates slight inhibition of 2B6 and 2E1. It is a potent inhibitor of CYP2D6 with an IC50 of ~0.46 μM in HLM (Dextromethorphan 5 μM) and 0.12 μM in rCYP2D6 (Bufuralol 5 μM)[1]. Additionally, Guanfu base A inhibits HERG channel current in a concentration-, voltage-, and time-dependent manner with an IC50 of 1.64 mM, shifts the activation curve negatively, and accelerates channel inactivation without affecting the inactivation curve [2]. |
| In vivo | Beagle dogs administered Dextromethorphan (2 mg/mL) intravenously following a pretreatment with Guanfu base A injection exhibited diminished CYP2D metabolic activity. This was evidenced by the maximum concentration (Cmax) of dextrorphan being one-third compared to the saline-treated group and the area under the plasma concentration-time curve being half of that observed in the saline-treated group [1]. |
| Synonyms | Guan-fu base A |
| Molecular Weight | 429.5 |
| Formula | C24H31NO6 |
| Cas No. | 1394-48-5 |
| Smiles | [H][C@@]12CC34CC(=C)[C@]5([H])[C@@H](O)[C@@]3([H])[C@@]36C[C@H](C[C@@](C)(CN1C3[C@@]4(O)[C@@H]5OC(C)=O)[C@@]26[H])OC(C)=O |
| Relative Density. | 1.43 g/cm3 (Predicted) |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 10 mM, Sonication is recommended. | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.66 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.